Call for Applications for CORD Board of Directors

CORD is looking for passionate, creative, committed, qualified people to join our Board of Directors for the 2018-2021 term to help guide our organization meet the needs of the rare disease community. Please refer to the following link for the duties and expectations of a Director as well as frequently asked questions. Deadline to apply is May 17, 2018. Applications

Report on CCSN’s Ontario All-party Cancer Caucus, March 21, 2018

by Jaymee Maaghop, CCSN Public Policy Assistant The Canadian Cancer Survivor Network hosted its second All-party Cancer Caucus meeting with members of the Ontario legislature at Queen’s Park, Toronto on March 21, 2018, with participants continuing discussions on the topic of rehabilitative services for the side effects of cancer and its treatments. There were many

Health Care on Trial – Sign the Open Letter to Brian Day

On April 9, a court case resumes in British Columbia that seeks to overturn the ban on private for-profit health care. This case will likely  end up in the Supreme Court of Canada and threaten our entire public health care system. Brian Day, CEO of a private for-profit clinic is seeking to have health care legislation

Click here to watch our most recent webinar: Improving Access to Innovative Cancer Therapies in Canada

The slides for this webinar are available on our Slideshare account.  Robin Markowitz and Elizabeth Lye from Lymphoma Canada discussed recent pCODR drug funding requests for innovative cancer therapies and how negative funding recommendations are affecting patient access to effective new treatments. The presentation was followed by an interactive question and answer session. Originally broadcast on

Breast Cancer Caregiver Survey: Women Being Treated with Herceptin-Perjeta Combination Therapy

The pan-Canadian Oncology Drug Review (pCODR) makes recommendations about whether the provincial health plans should pay for new cancer drugs. pCODR will soon be reviewing the use of Herceptin-Perjeta combination therapy to treat HER2-positive early breast cancer. Rethink Breast Cancer will be making a submission to ensure that patient voices are represented and considered during the